BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29434060)

  • 1. Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
    Goyal A; Singh H; Sehgal VK; Jayanthi CR; Munshi R; Bairy KL; Kumar R; Kaushal S; Kakkar AK; Ambwani S; Goyal C; Mazumdar G; Adhikari A; Das N; Stephy DJ; Thangaraju P; Dhasmana DC; Rehman SU; Chakrabarti A; Bhandare B; Badyal DK; Kaur I; Chandrashekar K; Singh J; Dhamija P; Sarangi SC; Gupta YK
    Indian J Med Res; 2017 Oct; 146(4):468-475. PubMed ID: 29434060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.
    Pai SA; Kshirsagar NA
    Indian J Med Res; 2016 Nov; 144(5):672-681. PubMed ID: 28361819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone use and risk of bladder cancer: population based cohort study.
    Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
    BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. India suspends pioglitazone: is it justified?
    Sadikot SM; Ghosal S
    Diabetes Metab Syndr; 2014; 8(1):53-6. PubMed ID: 24661760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eight cases of bladder cancer in pioglitazone users from India.
    Unnikrishnan R; Sundramoorthy C; Deshpande N; Sarvothaman R; Sahay RK; Mehtalia S; Venkatraman JV; Mohan V
    J Assoc Physicians India; 2012 Dec; 60():66. PubMed ID: 23781679
    [No Abstract]   [Full Text] [Related]  

  • 8. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
    Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
    JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
    Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
    Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
    Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
    BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational follow-up of the PROactive study: a 6-year update.
    Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
    Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
    Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
    Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
    Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
    Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
    Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
    Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
    He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
    Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
    Bhushan S; Ray RS; Prakash J; Singh GN
    Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone and bladder cancer: the pros and cons.
    Panikar V
    J Assoc Physicians India; 2012 Jan; 60():72-3. PubMed ID: 22715550
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
    Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
    Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
    Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.